[1]黄吉凤 何永铭.非缺血性心肌病室性心动过速导管消融的研究进展[J].心血管病学进展,2023,(5):430.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.011]
 HUANG Jifeng,HE Yongming.Catheter Ablation of Ventricular Tachycardia in Non-ischemic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2023,(5):430.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.011]
点击复制

非缺血性心肌病室性心动过速导管消融的研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年5期
页码:
430
栏目:
综述
出版日期:
2023-05-25

文章信息/Info

Title:
Catheter Ablation of Ventricular Tachycardia in Non-ischemic Cardiomyopathy
作者:
黄吉凤 何永铭
(陆军军医大学第二附属医院心内科,重庆 400037)
Author(s):
HUANG Jifeng HE Yongming
(Department of Cardiology,The Second Affiliated Hospital of Army Medical University,Chongqing 400037,China)
关键词:
非缺血性心肌病室性心动过速导管消融
Keywords:
Non-ischemic cardiomyopathy Ventricular tachycardia Catheter ablation
DOI:
10.16806/j.cnki.issn.1004-3934.2023.05.011
摘要:
非缺血性心肌病室性心动过速的发病机制主要是瘢痕折返,瘢痕常累及心肌中层及心外膜。非缺血性心肌病室性心动过速多次消融的累积成功率为70%~80%,但LMNA基因突变心肌病及肥厚型心肌病扩张期室性心动过速消融的成功率较低。非缺血性心肌病室性心动过速导管消融手术的并发症发生率并不高于缺血性心肌病室性心动过速。术中晚电位消除+室速不能被诱发这一消融策略可增加手术的成功率。现对非缺血性心肌病室性心动过速导管消融的有效性及安全性做一综述。
Abstract:
The pathogenesis of ventricular tachycardia in non-ischemic cardiomyopathy is mainly scar-related reentry,which often involves the intramural and epicardium. The cumulative success rate of multiple ablation of ventricular tachycardia in non-ischemic cardiomyopathy can reach about 70%~80%,but the success rate of LMNA mutation cardiomyopathy and the dilated phase of hypertrophic cardiomyopathy is low. The complication rate of catheter ablation for ventricular tachycardia with non-ischemic cardiomyopathy is not higher than that of ventricular tachycardia with ischemic cardiomyopathy. The ablation strategy of late potential ablation and ventricular tachycardia noninducibility can increase the success rate. This article reviews the efficacy and safety of catheter ablation for ventricular tachycardia in non-ischemic cardiomyopathy

参考文献/References:

[1] Brigden W. Uncommon myocardial diseases:the non-coronary cardiomyopathies[J]. Lancet,1957,273(7008):1243-1249.

[2] Cronin EM,Bogun FM,Maury P,et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias[J]. J Interv Card Electrophysiol,2020,59(1):145-298.

[3] Kanagaratnam A,Virk SA,Pham T,et al. Catheter ablation for ventricular tachycardia in ischaemic versus non-ischaemic cardiomyopathy:a systematic review and meta-analysis[J]. Heart Lung Circ,2022,31(8):1064-1074.

[4] Bhaskaran A,Tung R,Stevenson WG,et al. Catheter ablation of VT in non-ischaemic cardiomyopathies:endocardial,epicardial and intramural approaches[J]. Heart Lung Circ,2019,28(1):84-101.

[5] Liuba I,Marchlinski FE. The substrate and ablation of ventricular tachycardia in patients with nonischemic cardiomyopathy[J]. Circ J,2013,77(8):1957-1966.

[6] Kotake Y,Nalliah CJ,Campbell T,et al. Comparison of the arrhythmogenic substrate for ventricular tachycardia in patients with ischemic vs non-ischemic cardiomyopathy-insights from high-density,multi-electrode catheter mapping[J]. J Interv Card Electrophysiol,2023,66(1):5-14.

[7] Chakarov I,Mueller J,Ene E,et al. Long-term outcomes after catheter ablation of ventricular tachycardia in dilated vs. ischemic cardiomyopathy[J]. J Clin Med,2022,11(14):4000.

[8] Muser D,Santangeli P,Castro SA,et al. Long-term outcome after catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy[J]. Circ Arrhythm Electrophysiol,2016,9(10):e004328.

[9] Porcu M,Corda M,Pasqualucci D,et al. A very long-term observation of a family with dilated cardiomyopathy and overlapping phenotype from lamin A/C mutation[J]. J Cardiovasc Med (Hagerstown),2021,22(1):53-58.

[10] Kumar S,Androulakis AF,Sellal JM,et al. Multicenter experience with catheter ablation for ventricular tachycardia in lamin A/C cardiomyopathy[J]. Circ Arrhythm Electrophysiol,2016,9(8):e004357.

[11] Zeppenfeld K,Tfelt-Hansen J,de Riva M,et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J,2022,43(40):3997-4126.

[12] Santangeli P,Zado ES,Supple GE,et al. Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy[J]. Circ Arrhythm Electrophysiol,2015,8(6):1413-1421.

[13] Mathew S,Saguner AM,Schenker N,et al. Catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia:a sequential approach[J]. J Am Heart Assoc,2019,8(5):e010365.

[14] Romero J,Patel K,Briceno D,et al. Endo-epicardial ablation vs endocardial ablation for the management of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy:A systematic review and meta-analysis[J]. J Cardiovasc Electrophysiol,2020,31(8):2022-2031.

[15] Liang E,Wu L,Fan S,et al. Catheter ablation of arrhythmogenic right ventricular cardiomyopathy ventricular tachycardia:18-year experience in 284 patients[J]. Europace,2020,22(5):806-812.

[16] Dukkipati SR,d’Avila A,Soejima K,et al. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy[J]. Circ Arrhythm Electrophysiol,2011,4(2):185-194.

[17] Maron MS,Finley JJ,Bos JM,et al. Prevalence,clinical significance,and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy[J]. Circulation,2008,118(15):1541-1549.

[18] Igarashi M,Nogami A,Kurosaki K,et al. Radiofrequency catheter ablation of?ventricular tachycardia in patients with hypertrophic cardiomyopathy and?apical aneurysm[J]. JACC Clin Electrophysiol,2018,4(3):339-350.

[19] Naeemah QJ,Komatsu Y,Nogami A,et al. Catheter ablation of ventricular tachycardia in dilated-phase hypertrophic cardiomyopathy:Substrate characterization and ablation outcome[J]. Pacing Clin Electrophysiol,2022,45(6):773-785.

[20] Tung R,Xue Y,Chen M,et al. First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation:the PAUSE-SCD randomized trial[J]. Circulation,2022,145(25):1839-1849.

[21] Della Bella P,Baratto F,Vergara P,et al. Does timing of ventricular tachycardia ablation affect prognosis in patients with an implantable cardioverter defibrillator?Results from the multicenter randomized PARTITA triall[J]. Circulation,2022,145(25):1829-1838.

[22] Ravi V,Poudyal A,Khanal S,et al. A systematic review and meta-analysis comparing radiofrequency catheter ablation with medical therapy for ventricular tachycardia in patients with ischemic and non-ischemic cardiomyopathies[J]. J Interv Card Electrophysiol,2023,66(1):161-175.

[23] Ding WY,Pearman CM,Bonnett L,et al. Complication rates following ventricular tachycardia ablation in ischaemic and non-ischaemic cardiomyopathies:a systematic review[J]. J Interv Card Electrophysiol,2022,63(1):59-67.

[24] Sciria CT,Kogan EV,Ip JE,et al. Trends and outcomes of catheter ablation of ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy[J]. Circ Arrhythm Electrophysiol,2022,15(4):e010742.

[25] Silberbauer J,Oloriz T,Maccabelli G,et al. Noninducibility and late potential abolition:a novel combined prognostic procedural end point for catheter ablation of postinfarction ventricular tachycardia[J]. Circ Arrhythm Electrophysiol,2014,7(3):424-435.

[26] Okubo K,Gigli L,Trevisi N,et al. Long-term outcome after ventricular tachycardia ablation in nonischemic cardiomyopathy:late potential abolition and VT noninducibility[J]. Circ Arrhythm Electrophysiol,2020,13(8):e008307.

相似文献/References:

[1]李才垚 王洪涛 秦兴华 刘鹏 郑强荪.心肌梗死后室性心动过速导管消融适应证在指南共识中的演变[J].心血管病学进展,2021,(5):421.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.009]
 LI Caiyao,WANG Hongtao,QIN Xinghua,et al.Evolution of Indications for Ablation of Ventricular Tachycardia after Myocardial Infarction in Guidelines and Consensus[J].Advances in Cardiovascular Diseases,2021,(5):421.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.009]
[2]王思博 王连生.心肌梗死后室性心律失常的治疗进展[J].心血管病学进展,2021,(6):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]
 WANG SiboWANG Liansheng.Treatment of Ventricular Arrhythmias after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(5):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]
[3]王芯梦 崔凯军.心脏磁共振成像在室性心动过速消融治疗中的应用进展[J].心血管病学进展,2024,(1):48.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.013]
 WANG Xinmeng,CUI Kaijun.Cardiac Magnetic Resonance Applied in Ablation of Ventricular Tachycardia[J].Advances in Cardiovascular Diseases,2024,(5):48.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.013]
[4]曹奕辉 李剑 周鹏.室性心动过速导管消融术后血栓栓塞预防治疗的研究进展[J].心血管病学进展,2024,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.001]
 CAO Yihui,LI Jian,ZHOU Peng.Recent Advances in Thromboembolism Prophylaxis after?atheter Ablation of Ventricular Tachycardia[J].Advances in Cardiovascular Diseases,2024,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.001]

更新日期/Last Update: 2023-06-29